All In Biotech

Drug Trial Radar · NCT05450965

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Jul 19, 2022

Primary completion

Aug 31, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cardiff Oncology; National Cancer Institute (NCI)
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.

Conditions

  • Small-cell Lung Cancer
  • Small Cell Lung Carcinoma

Interventions

  • OnvansertibDrug

    Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 42 months (cohort)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.